Extended Data Table 2 Summary of firsta events in event-free survival analysis

From: Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial

Patients, n (%)

Atezolizumab + CT (n = 165)

Placebo + CT (n = 168)

Disease progression (during neoadjuvant phase, before surgery)

5 (3.0)

7 (4.2)

 Primary tumor progression

0

4 (2.4)

 Local progression

2 (1.2)

1 (0.6)

 Regional progression

1 (0.6)

2 (1.2)

 Distant progression

2 (1.2)

0

Disease recurrence (after surgery)

24 (14.5)

25 (14.9)

 Local recurrence

7 (4.2)

2 (1.2)

 Regional recurrence

3 (1.8)

4 (2.4)

 Distant recurrence

13 (7.9)

19 (11.3)

 Second primary invasive breast malignancy

1 (0.6)

0

Death (as first event at any time)

2 (1.2)

9 (5.4)

  1. aIf more than one type of progression/recurrence was reported at the first timepoint, the most unfavorable event is reported.
Back to article page